Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPSE | Q9Y251 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20280936 | 1.00 | HPSE (1.00) | HPSE | |
| SCHEMBL6821029 | 1.00 | HPSE (1.00) | HPSE | |
| SCHEMBL6821869 | 0.94 | HPSE (0.89) | HPSE | |
| SCHEMBL6821844 | 0.92 | HPSE (1.00) | HPSE | |
| SCHEMBL6822223 | 0.90 | HPSE (0.90) | HPSE | |
| SCHEMBL6822193 | 0.90 | HPSE (1.00) | HPSE | |
| SCHEMBL6822288 | 0.89 | HPSE (1.00) | HPSE | |
| SCHEMBL6824237 | 0.89 | HPSE (1.00) | HPSE | |
| SCHEMBL7118415 | 0.89 | HPSE (0.87) | HPSE | |
| SCHEMBL6818350 | 0.88 | HPSE (0.83) | HPSE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 114 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12637473-B2 | MDM2 protein degraders | REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2026-05-26 | — | — | US | disclosed |
| US-12637415-B2 | Lyophilized composition comprising (s)-isopropyl 2-((s)-2-acetamido-3-(1H-indol-3-yl)propanamido)-6-diazo-5-oxohexanoate for intravenous administration and the use thereof | DRACEN PHARMACEUTICALS, INC. (US) | 2026-05-26 | — | — | US | disclosed |
| US-12616679-B2 | Lyophilized composition comprising (s)-isopropyl 2-((s)-2-acetamido-3-(1H-indol-3-yl)propanamido)-6-diazo-5-oxohexanoate for subcutaneous administration and the use thereof | DRACEN PHARMACEUTICALS, INC. (US) | 2026-05-05 | — | — | US | disclosed |
| US-12577245-B2 | Sulfonyl benzamide derivatives as Bcl-2 inhibitors | ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) | 2026-03-17 | — | — | US | disclosed |
| US-12570679-B2 | STAT3 protein degraders | REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2026-03-10 | — | — | US | disclosed |
| US-20260055097-A9 | NRF2 PROTEIN DEGRADERS | GANYMEDE ONCOLOGY INC (US) | 2026-02-26 | — | — | US | disclosed |
| US-12522623-B2 | Small molecule STAT protein degraders | REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2026-01-13 | — | — | US | disclosed |
| US-20250295638-A1 | METHODS OF TREATING ALLOGRAFT REJECTION | BARGENT THERAPEUTICS PTY LTD (AU) | 2025-09-25 | — | — | US | disclosed |
| US-20250276993-A1 | PSEUDO-DISACCHARIDE COMPOUNDS | UNIVERSITEIT LEIDEN (NL) | 2025-09-04 | — | — | US | disclosed |
| US-20250215039-A1 | NUCLEOSIDES FOR TREATING CANCER | PRIMEFOUR THERAPEUTICS INC (US) | 2025-07-03 | — | — | US | disclosed |
| EP-3569601-B1 | N-(PHENYLSULFONYL)BENZAMIDES AND RELATED COMPOUNDS AS BCL-2 INHIBITORS | UNIV MICHIGAN REGENTS (US) | 2022-06-22 | — | — | EP | disclosed |
| US-11365186-B2 | Substituted benzimidazoles, their preparation and their use as pharmaceuticals | EPIGENETIX, INC. (US) | 2022-06-21 | — | — | US | disclosed |
| US-20220185831-A1 | STAT3 PROTEIN DEGRADERS | UNIV MICHIGAN REGENTS (US) | 2022-06-16 | — | — | US | disclosed |
| EP-3999510-A1 | IMIDAZOPYRIMIDINES AS EED INHIBITORS AND THE USE THEREOF | The Regents Of The University Of Michigan (US) | 2022-05-25 | — | — | EP | disclosed |
| EP-4001273-A2 | AMINOPYRIMIDINES AS ALK INHIBITORS | The Regents Of The University Of Michigan (US) | 2022-05-25 | — | — | EP | disclosed |
| US-20220117938-A1 | COMBINATON THERAPY WITH A DON PRODRUG AND AN IMMUNE CHECKPOINT INHIBITOR | DRACEN PHARMACEUTICALS, INC. | 2022-04-21 | — | — | US | disclosed |
| EP-3983084-A1 | AMINO ACID TRANSPORT INHIBITORS AND THE USES THEREOF | Vanderbilt University (US) | 2022-04-20 | — | — | EP | disclosed |
| EP-3983377-A1 | DIBENZYLAMINES AS AMINO ACID TRANSPORT INHIBITORS | Vanderbilt University (US) | 2022-04-20 | — | — | EP | disclosed |
| WO-2022066882-A1 | METHOD FOR TREATING CANCER WITH A REVERSE TRANSCRIPTASE INHIBITOR | ONCOLINEA PHARMACEUTICALS, INC. (US) | 2022-03-31 | — | — | WO | disclosed |
| US-11267822-B2 | BET bromodomain protein degraders with cleavable linkers | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2022-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12637473-B2 | MDM2 protein degraders | MDM2, TP53, TP53BP1 | HPSE 3730/4885 |
| US-12577245-B2 | Sulfonyl benzamide derivatives as Bcl-2 inhibitors | BCL2A1, BCL2L1, BCL2L11 | HPSE 3313/4885 |
| US-11365186-B2 | Substituted benzimidazoles, their preparation and their use as pharmaceuticals | BRD3, BRDT, BRD4 | HPSE 3410/4885 |
| US-11267822-B2 | BET bromodomain protein degraders with cleavable linkers | BRD4, BET1, BRWD1 | HPSE 3059/4885 |
| US-20220117938-A1 | COMBINATON THERAPY WITH A DON PRODRUG AND AN IMMUNE CHECKPOINT INHIBITOR | PDCD1, CD274, BID | HPSE 2612/4885 |
| US-20220185831-A1 | STAT3 PROTEIN DEGRADERS | STAT3, JAK2, STAT5A | HPSE 2450/4885 |
| US-12570679-B2 | STAT3 protein degraders | STAT3, JAK2, IL6ST | HPSE 2433/4885 |
| US-20250276993-A1 | PSEUDO-DISACCHARIDE COMPOUNDS | HPSE, HEXD, HEXA | HPSE 1/4885 |
| US-12616679-B2 | Lyophilized composition comprising (s)-isopropyl 2-((s)-2-acetamido-3-(1H-indol-3-yl)propanamido)-6-diazo-5-oxohexanoate for subcutaneous administration and the use thereof | GLUL, QPCT, QPCTL | HPSE 4645/4885 |
| US-20250215039-A1 | NUCLEOSIDES FOR TREATING CANCER | UNG, OGG1, NTPCR | HPSE 1047/4885 |
| US-20250295638-A1 | METHODS OF TREATING ALLOGRAFT REJECTION | CD74, TST, SERPINB1 | HPSE 461/4885 |
| US-20260055097-A9 | NRF2 PROTEIN DEGRADERS | KEAP1, NFE2L2, NFE2 | HPSE 3229/4885 |
| US-12637415-B2 | Lyophilized composition comprising (s)-isopropyl 2-((s)-2-acetamido-3-(1H-indol-3-yl)propanamido)-6-diazo-5-oxohexanoate for intravenous administration and the use thereof | GLS, GLUL, GLS2 | HPSE 4627/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.